ISSN 0378-6986

Official Journal

of the European Communities

C 178

Volume 45

26 July 2002

English edition

Information and Notices

[1] Text with EEA relevance

(Continued overleaf)

Notice No | Contents (continued) | Page

EN

I

(Information)

COMMISSION

Euro exchange rates [1]

25 July 2002

(2002/C 178/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,0014	LVL	Latvian lats	0,5977
JPY	Japanese yen	116,8	MTL	Maltese lira	0,4166
DKK	Danish krone	7,4337	PLN	Polish zloty	4,0833
GBP	Pound sterling	0,636	ROL	Romanian leu	32843
SEK	Swedish krona	9,4182	SIT	Slovenian tolar	226,856
CHF	Swiss franc	1,4494	SKK	Slovak koruna	44,724
ISK	Iceland króna	85,39	TRL	Turkish lira	1684000
NOK	Norwegian krone	7,547	AUD	Australian dollar	1,8495
BGN	Bulgarian lev	1,9463	CAD	Canadian dollar	1,5713
CYP	Cyprus pound	0,57521	HKD	Hong Kong dollar	7,8108
CZK	Czech koruna	30,34	NZD	New Zealand dollar	2,1451
EEK	Estonian kroon	15,6466	SGD	Singapore dollar	1,7469
HUF	Hungarian forint	244,45	KRW	South Korean won	1162,53
LTL	Lithuanian litas	3,4525	ZAR	South African rand	10,1993

[1] *Source:* reference exchange rate published by the ECB.

Prior notification of a concentration

(Case COMP/M.2826 — Ahlsen/E.ON.JV)

(2002/C 178/02)

(Text with EEA relevance)

1. On 12 July 2002 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 [1], as last amended by Regulation (EC) No 1310/97 [2], by which the German undertakings Ahlsen AG (Ahlsen), belonging to Holcim Ltd, and E.ON Kraftwerke GmbH (EKW) acquire, within the meaning of Article 3(1)(b) of the Regulation, joint control of the undertaking BauMineral Herten GmbH (BauMineral) by way of purchase of securities.

2. The business activities of the undertakings concerned are:

— Ahlsen: Production of cement and concrete,

— EKW: Generation of energy,

— BauMineral: Wholesale of hard coal fly ash.

3. On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EEC) No 4064/89. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.2826 — Ahlsen/E.ON.JV, to:

European Commission,
Directorate-General for Competition,
Directorate B — Merger Task Force,
J-70,
B-1049 Brussels.

---

[1] OJ L 395, 30.12.1989, p. 1; corrigendum: OJ L 257, 21.9.1990, p. 13.

[2] OJ L 180, 9.7.1997, p. 1; corrigendum: OJ L 40, 13.2.1998, p. 17.

Prior notification of a concentration

(Case COMP/M.2832 — General Motors/Daewoo Motors)

(2002/C 178/03)

(Text with EEA relevance)

1. On 20 June 2002 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 [1], as last amended by Regulation (EC) No 1310/97 [2], by which the undertaking General Motors Corporation (GM, US) acquires, within the meaning of Article 3(1)(b) of the Regulation, control of parts of the undertaking Daewoo Motor Company Ltd (Daewoo, Korea), by way of purchase of assets through a newly created company.

2. The business activities of the undertakings concerned are:

— GM: Design, manufacture, marketing and supply of automotive vehicles, and interests in telecommunications, aerospace and defence, financial and insurance services, locomotives, automotive systems and heavy-duty automatic transmissions,

— Daewoo: Design, manufacture, marketing and supply of automotive vehicles.

3. On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EEC) No 4064/89. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.2832 — General Motors/Daewoo Motors, to:

European Commission,
Directorate-General for Competition,
Directorate B — Merger Task Force,
J-70,
B-1049 Brussels.

---

[1] OJ L 395, 30.12.1989, p. 1; corrigendum: OJ L 257, 21.9.1990, p. 13.

[2] OJ L 180, 9.7.1997, p. 1; corrigendum: OJ L 40, 13.2.1998, p. 17.

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June to 15 July 2002

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ([1]))

(2002/C 178/04)

— Issuing of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
20.6.2002	Pegasys	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/02/221/001-008	24.6.2002
20.6.2002	Tamiflu	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/02/222/001-002	24.6.2002

— Modification of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
17.6.2002	Prandin	Novo Nordisk A/S Novo Allé DK-2880 Bagsværd	EU/1/00/162/001-018	20.6.2002
17.6.2002	Humalog	Eli Lilly Nederland BV Grootslag 1-5 3991 RA Houten Nederland	EU/1/96/007/001-008 EU/1/96/007/010-019	20.6.2002
18.6.2002	Teslascan	Amersham Health AS Nycoveien 1-2 PO Box 4220 Nydalen N-0401 Oslo	EU/1/97/040/001-002	20.6.2002
19.6.2002	Iscover	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/070/001a, 001b, 002a, 002b, 003a, 003b	21.6.2002
19.6.2002	Plavix	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/98/069/001a, 001b, 002a, 002b, 003a, 003b	21.6.2002
20.6.2002	Xenical	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/98/071/001-006	24.6.2002

([1]) OJ L 214, 24.8.1993, p. 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
20.6.2002	Remicade	Centocor BV Einsteinweg 101 2333 CB Leiden Nederland	EU/1/99/116/001-003	27.6.2002
20.6.2002	Sustiva	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/99/110/001-005	24.6.2002
20.6.2002	Ketek	Aventis Pharma SA 20, avenue Raymond-Aron F-92160 Antony	EU/1/01/191/001-004	24.6.2002
20.6.2002	Levviax	Aventis Pharma SA 20, avenue Raymond-Aron F-92160 Antony	EU/1/01/192/001-004	24.6.2002
25.6.2002	ReFacto	Genetics Institute of Europe BV Fraunhoferstraße 15 D-82152 Planegg/Martinsried	EU/1/99/103/001-003	27.6.2002
27.6.2002	Quadramet	CIS bio international BP 32 F-91192 Gif-sur-Yvette Cedex (CEA-CEN Route Nationale 306, F-Sarclay)	EU/1/97/057/001	2.7.2002
28.6.2002	Zerit	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/96/009/001-009	4.7.2002
28.6.2002	Karvea	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/97/049/001-015	4.7.2002
28.6.2002	Karvezide	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/085/001-010	4.7.2002
9.7.2002	Lumigan	Allergan Pharmaceuticals (Ireland) Ltd Castlebar Road Westport County Mayo Ireland	EU/1/02/205/002	11.7.2002
10.7.2002	Sustiva	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/99/110/001-005	15.7.2002
10.7.2002	Vistide	Pharmacia Enterprises SA 6, Circuit de la Foire Internationale L-1347 Luxembourg	EU/1/97/037/001	15.7.2002
10.7.2002	Panretin	Ligand Pharmaceuticals UK Ltd Innovis House 108 High Street Crawley West Sussex RH10 1BB United Kingdom	EU/1/00/149/001	15.7.2002

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
10.7.2002	Agenerase	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/00/148/004	15.7.2002
11.7.2002	ViraferonPeg	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles	EU/1/00/132/031-050	15.7.2002
11.7.2002	PegIntron	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles	EU/1/00/131/031-050	15.7.2002
11.7.2002	Kineret	Amgen Europe BV Minervum 7061 4817 ZK Breda Nederland	EU/1/02/203/001-003	15.7.2002
11.7.2002	Targretin	Ligand Pharmaceuticals UK Ltd Innovis House 108 High Street Crawley West Sussex RH10 1BB United Kingdom	EU/1/01/178/001	15.7.2002
11.7.2002	Trazec	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/01/175/001-021	15.7.2002
11.7.2002	Starlix	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/01/174/001-021	15.7.2002
11.7.2002	Remicade	Centocor BV Einsteinweg 101 2333 CB Leiden Nederland	EU/1/99/116/001-003	15.7.2002
11.7.2002	Viramune	Boehringer Ingelheim International GmbH Binger Straße 173 D-55216 Ingelheim am Rhein	EU/1/97/055/001-002	15.7.2002
15.7.2002	Mabthera	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/98/067/001-002	17.7.2002
15.7.2002	NovoRapid	Novo Nordisk A/S Novo Allé DK-2880 Bagsværd	EU/1/99/119/001, EU/1/99/119/003, EU/1/99/119/005-011	17.7.2002
15.7.2002	HumaSPECT	KS Biomedix Ltd 1 Occam Court Surrey Research Park Guildford Surrey GU2 7HJ United Kingdom	EU/1/98/083/001	17.7.2002

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
15.7.2002	PegIntron	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles	EU/1/00/131/001-030	17.7.2002

— **Modification of a marketing authorisation (Article 34 of Regulation (EEC) No 2309/93): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
9.7.2002	Metacam	Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein	EU/2/97/004/003-005	11.7.2002
10.7.2002	Quadrisol	Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/97/005/008-009	15.7.2002
10.7.2002	Stronghold	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/2/99/014/001-011	15.7.2002
10.7.2002	Metacam	Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein	EU/2/97/004/006	15.7.2002
15.7.2002	Clomicalm	Novartis Tiergesundheit GmbH Industriestraße 30—34 D-65760 Eschborn	EU/2/98/007/001-003	17.7.2002

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products
7 Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom.

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 June to 15 July 2002

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council [1] *or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council* [2]*)*

(2002/C 178/05)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorisation	Member State concerned	Date of notification
26.6.2002	Midazolam	See Annex I	See Annex I	27.6.2002

— Lift of suspension of a marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorisation	Member State concerned	Date of notification
26.6.2002	Sertindole	See Annex II	See Annex II	27.6.2002

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES

Member State	Marketing authorisation holder address	Marketing authorisation holder telephone (contact person)	Marketing authorisation holder fax	Product name	Strength	Pharma-ceutical form	Route of administration	Packaging	Concentration	Package size
AUSTRIA	Roche Austria GmbH Engelhorngasse 3 A-1211 Wien	(43-1) 27 73 92 89 C. Wachter	(43-1) 27 73 92 54	Dormicum	5 mg/5 ml 5 mg/1 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v., i.m., rectal 5 mg/1 ml — i.v., i.m., rectal 15 mg/3 ml — i.v., i.m., rectal 50 mg/10 ml — i.v., i.m., rectal	Glass ampoules white	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 5 mg/1 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
BELGIUM	NV Roche SA Rue Dante 75 B-1070 Bruxelles	(32-2) 525 82 41 A. De Wilde	(32-2) 525 82 95	Dormicum	5 mg/5 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v., i.m., rectal 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v., perfusion	Colourless Glass ampoules	5 mg/5 ml — 1 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 1 amps. 15 mg/3 ml — 2 amps. 50 mg/10 ml — 5 amps.
DENMARK	Roche a/s Industriholmen 59 DK-2650 Hvidovre	(45) 36 39 98 20 Johanna Nielsen	(45) 36 39 98 00	Dormicum	5 mg/5 ml 5 mg/1 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v. 5 mg/1 ml — i.v., i.m. 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v., i.m.	Glass ampoules	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 5 mg/1 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
FINLAND	Roche Oy Sinimäentie 10 A PO Box 12 FIN-02630 Espoo	(358-9) 52 53 33 32 S. Fagerstrom	(358-9) 52 53 33 50	Dormicum	5 mg/5 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v., i.m. 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v.	Glass ampoules	5 mg/5 ml — 1 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.

Member State	Marketing authorisation holder address	Marketing authorisation holder telephone (contact person)	Marketing authorisation holder fax	Product name	Strength	Pharma-ceutical form	Route of administration	Packaging	Concentration	Package size
FRANCE	Produits Roche 52, bd du Parc F-92521 Neuilly-sur-Seine Cedex	(33-1) 46 40 27 92 B. Marchenay	(33-1) 46 40 52 66	(Versed for 2 mg/2 ml) Hypnovel	2 mg/2 ml 5 mg/5 ml 5 mg/1 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	2 mg/2 ml — i.v. 5 mg/5 ml — i.v., i.m., rectal 5 mg/1 ml — i.m., rectal 15 mg/3 ml — i.m., rectal 50 mg/10 ml — i.v.	Glass ampoules	2 mg/2 ml — 1 mg/ml 5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	2 mg/2 ml — 2 amps. 5 mg/5 ml — 1, 6 amps. 5 mg/1 ml — 6 amps. 15 mg/3 ml — 6 amps. 50 mg/10 ml — 1, 6 amps.
GERMANY	Hoffmann-La Roche AG Emil-Barell-Straße 1 Postfach 1270 D-79639 Grenzach-Wyhlen	(49-762) 414 33 10 A. Zeissler	(49-762) 414 54 36	Dormicum	5 mg/5 ml 5 mg/1 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.m. or i.v. injection 5 mg/1 ml — i.m. or i.v. injection 15 mg/3 ml — i.m. or i.v. injection 50 mg/10 ml — i.v. injection	Colourless type I glass ampoules	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 5 amps. 5 mg/1 ml — 5, 25 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
GREECE	Roche (Hellas) SA 4, Alamanas & Delfon Street GR-15125 Maroussi	(30-1) 616 61 56 K. Tzogani	(30-1) 619 64 92	Dormicum	5 mg/5 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v., i.m., rectal 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v.	Glass ampoules	5 mg/5 ml — 1 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
ICELAND	F. Hoffmann-La Roche Ltd CH-4070 Basel	(45) 36 39 98 20 Johanna Nielsen (Roche Denmark)	(45) 36 39 98 00	Dormicum	5 mg/5 ml 5 mg/1 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v. 5 mg/1 ml — i.v., i.m. 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v., i.m.	Glass ampoules	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 5 mg/1 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.

Member State	Marketing authorisation holder address	Marketing authorisation holder telephone (contact person)	Marketing authorisation holder fax	Product name	Strength	Pharma-ceutical form	Route of administration	Packaging	Concentration	Package size
IRELAND	Roche Products Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	(44-1707) 36 56 10 C. Robson	(44-1707) 37 78 38	Hypnovel	10 mg/2 ml 10 mg/5 ml	Solution for injection	10 mg/2 ml — i.v., i.m. 10 mg/5 ml — i.v.	Glass ampoules	10 mg/2 ml — 5 mg/ml 10 mg/5 ml — 2 mg/ml	10 mg/2 ml — 10 amps. 10 mg/5 ml — 10 amps.
ITALY	Roche SpA Piazza Durante, 11 I-20131 Milano	(39-03) 92 47 44 36 A. Chiarotti	(39-03) 92 47 47 40	Ipnovel	5 mg/1 ml 15 mg/3 ml	Solution for injection	5 mg/1 ml — i.v., i.m. 15 mg/3 ml — i.v., i.m.	Ampoules	5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml	5 mg/1 ml — 1 amps. 15 mg/3 ml — 1 amps.
LUXEMBOURG	NV Roche SA Rue Dante, 75 B-1070 Bruxelles	(32-2) 525 82 41 A. De Wilde	(32-2) 525 82 95	Dormicum	5 mg/5 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v., i.m., rectal 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v., perfusion	Glass ampoules	5 mg/5 ml — 1 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 1 amp. 15 mg/3 ml — 2 amps. 50 mg/10 ml — 5 amps.
NETHERLANDS	Roche Nederland BV Nijverheidsweg 38 PO Box 42 3640 AA Mijdrecht Nederland	(31) 297 23 20 94 T. Van Oesch	(31) 297 23 20 93	Dormicum	5 mg/5 ml 5 mg/1 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/5 ml — i.v., i.m. 5 mg/1 ml — i.v., i.m. 15 mg/3 ml — i.v., i.m. 50 mg/10 ml — i.v., i.m.	Ampoules	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 5 mg/1 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
NORWAY	F. Hoffmann-La Roche Ltd CH-4070 Basel	(47) 22 78 90 34 M. Stroem	(47) 22 78 90 99	Dormicum	5 mg/5 ml 5 mg/1 ml 15 mg/3 ml	Solution for injection	5 mg/5 ml — i.m. 5 mg/1 ml — i.v. 15 mg/3 ml — i.v.	Ampoules	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 5 mg/1 ml — 10 amps. 15 mg/3 ml — 10 amps.

Member State	Marketing authorisation holder address	Marketing authorisation holder telephone (contact person)	Marketing authorisation holder fax	Product name	Strength	Pharma-ceutical form	Route of administration	Packaging	Concentration	Package size
PORTUGAL	Roche Farmacêutica Quimica, Lda Estrada Nacional, 249-1 P-2720-413 Amadora	(351) 214 25 70 97 Clara Saragoca	(351) 214 18 66 77	Dormicum	15 mg/3 ml 50 mg/10 ml	Solution for injection	15 mg/3 ml — i.v., i.m., infusion, rectal 50 mg/10 ml — i.v., i.m., infusion, rectal	Glass ampoules type I	15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
SPAIN	Productos Roche, SA Josefa Valcárcel, 42 E-28027 Madrid	(34-91) 324 82 53 A. Rivas	(34-91) 324 81 54	Dormicum	5 mg/5 ml 15 mg/3 ml	Solution for injection	5 mg/5 ml — i.v., i.m., rectal 15 mg/3 ml — i.v., i.m.	Glass ampoules type I	5 mg/5 ml — 1 mg/ml 15 mg/3 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 15 mg/3 ml — 5 amps.
SWEDEN	Roche AB Box 47327 S-100 74 Stockholm	(46-8) 726 12 95 L. Knoph	(46-8) 744 06 81	Dormicum	5 mg/1 ml 5 mg/5 ml 15 mg/3 ml 50 mg/10 ml	Solution for injection	5 mg/1 ml — i.v. 5 mg/5 ml — i.v. 15 mg/3 ml — i.v. 50 mg/10 ml — i.v.	Glass ampoules type I	5 mg/5 ml — 1 mg/ml 5 mg/1 ml — 5 mg/ml 15 mg/3 ml — 5 mg/ml 50 mg/10 ml — 5 mg/ml	5 mg/5 ml — 10 amps. 5 mg/1 ml — 10 amps. 15 mg/3 ml — 5 amps. 50 mg/10 ml — 5 amps.
UNITED KINGDOM	Roche Products Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	(44-707) 36 56 10 C. Robson	(44-1707) 37 78 38	Hypnovel	10 mg/2 ml 10 mg/5 ml	Solution for injection	10 mg/2 ml — i.v., i.m. 10 mg/5 ml — i.v.	Glass ampoules	10 mg/2 ml — 5 mg/ml 10 mg/5 ml — 2 mg/ml	10 mg/2 ml — 10 amps. 10 mg/5 ml — 10 amps.

ANNEX II

LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, STRENGTHS, PHARMACEUTICAL FORMS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES

SERTINDOLE-CONTAINING MEDICINAL PRODUCTS WITH MARKETING AUTHORISATION IN THE EUROPEAN UNION

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
AUSTRIA	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 4 mg Filmtabletten	4 mg	Film-coated tablet	Oral use	Blister Polypropylene container	30 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 8 mg Filmtabletten	8 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 12 mg Filmtabletten	12 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 16 mg Filmtabletten	16 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 20 mg Filmtabletten	20 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 24 mg Filmtabletten	24 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
BELGIUM	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
BELGIUM (*cont'd*)	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
DENMARK	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
FINLAND	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister Polypropylene container	30 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Not applicable	Not applicable
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister Polypropylene container	28 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Orale use	Blister Polypropylene container	28 100

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
FINLAND (*cont'd*)	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Not applicable	Not applicable
GERMANY	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Zerdol 4 mg	4 mg	Film-coated tablet	Oral use	Blister	20 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Zerdol 8 mg	8 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Zerdol 12 mg	12 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Zerdol 16 mg	16 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Zerdol 20 mg	20 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Zerdol 24 mg	24 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 4 mg	4 mg	Film-coated tablet	Oral use	Blister	20 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 8 mg	8 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 12 mg	12 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 16 mg	16 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 20 mg	20 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
GERMANY (*cont'd*)	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 24 mg	24 mg	Film-coated tablet	Oral use	Blister	20 50 100 (5 × 20)
GREECE	Lundbeck Hellas Kifisias 64 GR-15125 Marousi	Serdolect	4 mg	Film-coated tablet	Oral use	Blister	30
	Lundbeck Hellas Kifisias 64 GR-15125 Marousi	Serdolect	8 mg	Film-coated tablet	Oral use	Blister	20 28
	Lundbeck Hellas Kifisias 64 GR-15125 Marousi	Serdolect	12 mg	Film-coated tablet	Oral use	Blister	20 28
	Lundbeck Hellas Kifisias 64 GR-15125 Marousi	Serdolect	16 mg	Film-coated tablet	Oral use	Blister	20 28
	Lundbeck Hellas Kifisias 64 GR-15125 Marousi	Serdolect	20 mg	Film-coated tablet	Oral use	Blister	20 28
	Lundbeck Hellas Kifisias 64 GR-15125 Marousi	Serdolect	24 mg	Film-coated tablet	Oral use	Blister	20 28
IRELAND	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
ITALY	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
LUXEMBOURG	Lundbeck SA 225 Avenue Molière B-1050 Brussels	Serdolect	4 mg	Film-coated tablet	Oral use	Blister	30
	Lundbeck SA 225 Avenue Molière B-1050 Brussels	Serdolect	12 mg	Film-coated tablet	Oral use	Blister	28
	Lundbeck SA 225 Avenue Molière B-1050 Brussels	Serdolect	16 mg	Film-coated tablet	Oral use	Blister	28
	Lundbeck SA 225 Avenue Molière B-1050 Brussels	Serdolect	20 mg	Film-coated tablet	Oral use	Blister	28
NETHERLANDS	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 4 mg	4 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 8 mg	8 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 12 mg	12 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
NETHERLANDS (*cont'd*)	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 16 mg	16 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 20 mg	20 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect 24 mg	24 mg	Film-coated tablet	Oral use	Blister Polyproylene container	20, 28, 30, 50, 98, 100 100
PORTUGAL	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Coated tablet	Oral use	Blister	30
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Coated tablet	Oral use	Blister	28
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Coated tablet	Oral use	Blister	28
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Coated tablet	Oral use	Blister	28
SPAIN	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister	30 98
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Blister	28
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister	28
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister	28
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Oral use	Blister	28

Member State	Marketing authorisation holder	Product name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
SPAIN (*cont'd*)	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Blister	28
UNITED KINGDOM	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	4 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	8 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	12 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	16 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	20 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100
	H. Lundbeck A/S Ottiliavej 9 Valby DK-2500 Copenhagen	Serdolect	24 mg	Film-coated tablet	Oral use	Blister Polypropylene container	20, 28, 30, 50, 98, 100 100

Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty

Cases where the Commission raises no objections

(2002/C 178/06)

(Text with EEA relevance)

Date of adoption of the decision: 12.3.2002

Member State: Belgium

Aid No: E 1/01 (ex C 39/81)

Title: Law of 30 December 1970 on economic expansion (Articles 1, 2(b), 3-9, 18-25 and 30-48)

Objective: Promotion of the expansion of Belgian enterprises

Legal basis: Wet van 30 december 1970 betreffende de economische expansie/Loi du 30 décembre 1970 sur l'expansion économique

Duration: Unlimited time

Other information:

1. Form of interventions: Grants, interest rate subsidies, interest free advances, tax exemptions, accelerated depreciation allowances, State guarantees

2. The appropriate measures as accepted by the Belgian authorities are as follows:

   (a) after 30 September 2001, State aid will no longer be granted directly on the basis of Articles 1, 2(b), 3-9, 18-24, 33-41 and 43-48 of the Law of 30 December 1970

   (b) after 31 December 2001, State aid will no longer be granted directly on the basis of Articles 30, 31, 32 and 42 of the Law of 30 December 1970. After that same date, State aid will no longer be granted directly on the basis of Article 25 of the Law of 30 December 1970 in the NUTS level I regions of Flanders and Wallonia

   (c) after 31 May 2002, State aid will no longer be granted directly on the basis of Article 25 of the Law of 30 December 1970 in the NUTS level I region of Brussels

   (d) by 31 December 2003, Articles 1, 2(b), 3-9, 18-25 and 30-48 of the Law of 30 December 1970 will be abrogated

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 18.7.2001

Member State: Belgium

Aid No: E 2/01

Title: Law of 30 December 1970 on economic expansion, as modified by the (Walloon) Decree of 25 June 1992 (Articles 1 to 5 quater, 13 ter, 22 to 25, 29 bis to 48)

Objective: Promotion of the expansion of Walloon enterprises

Legal basis: Loi du 30 décembre 1970 sur l'expansion économique, modifiée par le décret wallon du 25 juin 1992/Wet van 30 december 1970 betreffende de economische expansie, zoals gewijzigd bij het (Waals) decreet van 25 juni 1992

Duration: Unlimited in time

Other information:

1. Form of interventions: grants, interest-rate subsidies, interest-free advances, tax exemptions, accelerated depreciation allowances, State guarantees

2. The Commission has decided to propose to the Belgian authorities, in accordance with Article 88(1) EC, the following appropriate measures in relation to the Law of 30 December 1970 on economic expansion, as modified by the (Walloon) Decree of 25 June 1992:

   (a) after 30 September 2001, State aid will no longer be granted directly on the basis of Articles 1 to 5 quater, Article 13 ter, Articles 22 to 24, Article 29 bis, Articles 33 to 41 and Articles 43 to 48 of the Law of 30 December 1970, as modified by the (Walloon) Decree of 25 June 1992

   (b) after 31 December 2001, State aid will no longer be granted directly on the basis of Articles 25, 30, 30 bis, 32, 32 bis and 42 of the Law of 30 December 1970, as modified by the (Walloon) Decree of 25 June 1992

   (c) by 31 December 2003, Articles 1 to 5 quater, Article 13 ter, Articles 22 to 25 and Articles 29 bis to 48 of the Law of 30 December 1970, as modified by the (Walloon) Decree of 25 June 1992 will be abrogated

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

Date of adoption of the decision: 19.6.2002

Member State: Austria

Aid No: N 643/01

Title: Programme of aid for the development of railway sidings

Objective: Financially support the construction, extension and modernisation of private railway sidings in Austria

Legal basis: Richtlinien; Programme zur Unterstützung des Ausbaus von Anschlussbahnen 1.1.2000—31.12.2006

Budget: Maximum EUR 8,7 million per year (ATS 120 million)

Duration: 2000-2006

Other information: Type of aid: Capital grants

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at

http://europa.eu.int/comm/secretariat_general/sgb/state_aids

III

(Notices)

COMMISSION

Growth and audiovisual: i2i audiovisual — 2002

Measures to encourage access to external funding from banks and financial institutions for independent European production companies

Call for proposals DG EAC 29/02

(2002/C 178/07)

I. **Introduction**

This call for proposals is based on the preparatory action 'Growth and audiovisual: i2i audiovisual' in the EU's general budget for 2002 — preparatory action within the meaning of the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (OJ C 172, 18.6.1999, p. 1).

II. **Aim**

This call for proposals is open to independent European production companies located in the Member States of the European Union.

The support is intended in particular for independent European production companies with bank loans for financing the production of a work (discount) for their projects:

— either from a partner of the EIB group (i2i audiovisual initiative) [1],

— or from another bank or financial institution. In that case, the project concerned must have received development support (slate funding) under the MEDIA-Plus programme.

Independent European production companies with bank loans for financing the production of a work from a partner institution of the EIB group will be given priority.

The object of the support is to encourage access to external funding from banks and financial institutions for independent European production companies. The aims of the support are, in particular, to:

— reduce the cost of audiovisual insurance taken out for the production of a film or audiovisual work: **Module 1** — support for the item 'insurance' in a production budget,

— reduce the cost of the completion guarantee for the production of a film or audiovisual work: **Module 2** — support for the item 'completion guarantee' in a production budget,

— reduce the cost of bank loans (discount) for the production of a film or audiovisual work: **Module 3** — support for the item 'financing costs' in a production budget.

The 'production of a work' comprises the preparation phase, the production phase and the post-production phase until the delivery of the negative.

III. **Funding**

The budget earmarked to this call for proposals is EUR 1,1 million.

IV. **Applications**

The Directorate-General for Education and Culture, Unit C3 — Support for the film and audiovisual industry (MEDIA) is responsible for the implementation of the preparatory action 'Growth and audiovisual: i2i audiovisual'.

Parties wishing to respond to this call for proposals and to receive guidelines for submitting a proposal in order to obtain a financial contribution under the call for proposals 'Growth and audiovisual: i2i audiovisual', should send their application by mail or fax to:

European Commission
Mr Jacques Delmoly (office B100-4/20)
Head of Unit DG EAC/C3
B-1049 Brussels
Fax (32-2) 299 92 14.

The Commission will dispatch the documents within two working days of receipt of the application.

The deadline for the submission of applications to the address above is **20 September 2002**.

[1] The EIB group's partners in the i2i audiovisual initiative are shown on the EIB's website (www.eib.org 'Projects and Loans', 'Innovation 2000 Initiative', 'Audiovisual', 'Progress to date', 'Risk Sharing Global Loans' and 'Global Loan').

V. **Processing of the applications**

The following procedure will be used for processing the applications:

— receipt, registration and confirmation of receipt by the Commission,

— processing by the Commission,

— evaluation and selection proposal by a panel of experts,

— processing and final decision by the Commission,

— notification of results.

No information will be given before the final decision has been taken.

CORRIGENDA

Corrigendum to the call for proposals issued by the Commission of the European Communities for the co-financing in 2002 and 2003 of decentralised cooperation activities in the developing countries (Council Regulation (EC) No 1659/98 of 17 July 1998, amended and extended by the Regulation (EC) No 955/2002 of the European Parliament and of the Council of 13 May 2002)

(Official Journal of the European Communities C 165 of 11 July 2002)

(2002/C 178/08)

On page 42, point 7 is replaced by the following:

'7. **Eligibility: who may apply?**

For this call for proposals organisations that have their headquarters in the European Union and/or in a developing country are eligible, i.e. local authorities, NGO's, indigenous people's organisations, professional associations and local initiative groups, cooperatives, trade unions, women's or youth organisations, educational, cultural and research organisations or institutions, churches and any non-governmental association likely to contribute to development.'.

Corrigendum to the competent national authorities referred to in Article 2(b) of Council Regulation (EC) No 1338/2001

(Official Journal of the European Communities C 173 of 19 July 2002)

(2002/C 178/09)

On page 2, in the title:

for: 'EUROPEAN CENTRAL BANK',

read: 'COMMISSION

EUROPEAN CENTRAL BANK'.
